MXPA05006650A - Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos. - Google Patents

Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos.

Info

Publication number
MXPA05006650A
MXPA05006650A MXPA05006650A MXPA05006650A MXPA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A MX PA05006650 A MXPA05006650 A MX PA05006650A
Authority
MX
Mexico
Prior art keywords
compounds
independently
ring
indol
sulfonyl
Prior art date
Application number
MXPA05006650A
Other languages
English (en)
Inventor
Marie Berry Jane
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Publication of MXPA05006650A publication Critical patent/MXPA05006650A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Esta invencion se refiere a ciertos compuestos de 4-(1- (sulfonil)-1H-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos, incluyendo compuestos de la siguiente formula, los cuales son, entre otros, agentes antiproliferativos, agentes contra el cancer y/o inhibidores de tiorredoxina/tiorredoxina reductasa: (ver formula) en donde: Ar es un grupo 1-(sulfonil)-1H-indol-2-ilo; el enlace marcado a es independientemente: (a) un solo enlace o (b) un doble enlace; el enlace marcado ° es independientemente: (a) un solo enlace o (b) un doble enlace; el grupo -OR° es independientemente: (a) -OH; (b) un grupo de eter (por ejemplo, -OMe) o (c) un grupo aciloxi (es decir, ester inverso) (por ejemplo, -OC(=O)Me); cada uno de R2, R3, R5 y es independientemente un sustituyente de anillo y es: (a) H; (b) un sustituyente monodentado monovalente o (c) un sustituyente de anillo que, junto con un sustituyente de anillo adyacente, y junto con los atomos de anillo a los cuales estos sustituyentes de anillo estan unidos, forman un anillo fusionado; y sales, esteres, amidas, solvatos, hidratos y formas protegidas farmaceuticarnente aceptables de los mismos. La presente invencion se refiere tambien a composiciones farmaceuticas que comprenden estos compuestos, asi como al uso de estos compuestos y composiciones, tanto in vitro como in vivo, por ejemplo, en el tratamiento de condiciones proliferativas (por ejemplo cancer), y/o condiciones mediadas por tiorredoxina/tiorredoxina reductasa.
MXPA05006650A 2002-12-20 2002-12-20 Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos. MXPA05006650A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2002/005842 WO2004056361A1 (en) 2002-12-20 2002-12-20 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents

Publications (1)

Publication Number Publication Date
MXPA05006650A true MXPA05006650A (es) 2005-09-30

Family

ID=32670966

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006650A MXPA05006650A (es) 2002-12-20 2002-12-20 Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos.

Country Status (12)

Country Link
US (1) US7307099B2 (es)
EP (1) EP1572197B1 (es)
JP (1) JP4465281B2 (es)
CN (1) CN100363347C (es)
AT (1) ATE437639T1 (es)
AU (1) AU2002353193B2 (es)
BR (1) BR0215986A (es)
CA (1) CA2508275A1 (es)
DE (1) DE60233175D1 (es)
ES (1) ES2330205T3 (es)
MX (1) MXPA05006650A (es)
WO (1) WO2004056361A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136017A1 (en) * 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
CN102051406A (zh) * 2009-11-03 2011-05-11 凯熙医药(武汉)有限公司 一种用于预报人体发生异常增殖或肿瘤发生风险的检测方法
WO2023133507A1 (en) * 2022-01-07 2023-07-13 University Of Maryland, Baltimore Estradiol prodrugs and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414217A (en) 1981-11-23 1983-11-08 Riker Laboratories, Inc. 3,5-Di(t-butyl)-4-hydroxyphenyl substituted pyridines
US4535165A (en) * 1981-11-23 1985-08-13 Riker Laboratories, Inc. Substituted diazoles and thiazoles
US4357345A (en) * 1981-11-23 1982-11-02 Riker Laboratories, Inc. Substituted furans
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CA2091204C (en) * 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
US5391570A (en) * 1993-10-14 1995-02-21 Bristol-Myers Squibb Aminomethyl-benzodioxane and benzopyran serotonergic agents
MXPA02011926A (es) 2000-05-31 2003-04-22 Warner Lambert Co Ciclohexilaminas biciclicas y su uso como antagonistas de receptor de n-metil-d-aspartato.
GB0116594D0 (en) * 2001-07-06 2001-08-29 Cancer Res Ventures Ltd Therapeutic compounds

Also Published As

Publication number Publication date
US7307099B2 (en) 2007-12-11
ATE437639T1 (de) 2009-08-15
JP2006512351A (ja) 2006-04-13
EP1572197B1 (en) 2009-07-29
ES2330205T3 (es) 2009-12-07
US20060100265A1 (en) 2006-05-11
DE60233175D1 (de) 2009-09-10
CN100363347C (zh) 2008-01-23
JP4465281B2 (ja) 2010-05-19
BR0215986A (pt) 2005-11-01
CN1717233A (zh) 2006-01-04
EP1572197A1 (en) 2005-09-14
AU2002353193B2 (en) 2010-03-25
AU2002353193A1 (en) 2004-07-14
CA2508275A1 (en) 2004-07-08
WO2004056361A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2009000871A (es) Novedosos inhibidores de transcriptasa inversa de vih.
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
MX2009013804A (es) Inhibidores novedosos de transcriptasa inversa de vih.
MX2010007375A (es) Nuevos derivados de lupano.
TW200612909A (en) Compounds
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
HK1097189A1 (en) Cannabinoid receptor ligands
GEP20115199B (en) Phosphatidylinositol 3-kinase inhibitors and their use
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MX2009001660A (es) Compuestos de 2,5-dihidroxibenceno para el tratamiento de psoriasis.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
SE0402925D0 (sv) Novel Compounds
HUP0203422A2 (hu) Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
GB0116594D0 (en) Therapeutic compounds
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
MXPA05006650A (es) Compuestos de 4-(1-(sulfonil)-1h-indol-2-il)-4-(hidroxi)-ciclohexa-2,5-dienona y analogos de los mismos como agentes terapeuticos.
DE60114640D1 (en) Antithrombosemittel
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MX2021009206A (es) Terapias contra el cancer.
MX2023006176A (es) Nuevos derivados de indazol acetileno.
RS20050954A (en) Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration